Long-Term Follow-Up (LTFU) of Subjects Dosed With NTLA-2001

ConditionsTransthyretin-Related (ATTR) Familial Amyloid Polyneuropathy Transthyretin-Related (ATTR) Familial Amyloid Cardiomyopathy Wild-Type Transthyretin Cardiac Amyloidosis

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexAll

Age18+

SponsorIntellia Therapeutics

About this trial

This is a follow-up study of subjects who received NTLA-2001 in a previous clinical trial as an observational evaluation of the long-term effects of the investigational therapy.

Eligibility criteria

Qualifiers

A subject has completed or discontinued from an Intellia-sponsored clinical study in which a complete or partial dose of NTLA-2001 was received.

A subject has provided informed consent for the LTFU study.

Disqualifiers

None

Trial design

Treatments tested in this trial

Not listed

Trial groups

No trial groups listed

Locations

France

Clinical Trial Site Paris France

New Zealand

Clinical Trial Site Auckland New Zealand

Sweden

Clinical Trial Site Umeå Sweden

United Kingdom

Clinical Trial Site London United Kingdom

Sponsors and collaborators

Intellia Therapeutics

Lead sponsor

Source ClinicalTrials.gov